Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Chronic Thromboembolic Disease (CTED)Exercise Intolerance Post PEA Surgery
Interventions
DRUG

Adempas

After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.

Trial Locations (1)

80045

RECRUITING

University of Colorado, Anschutz Medical Campus, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT03409588 - Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty | Biotech Hunter | Biotech Hunter